Open References
Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008;359:366–377. [Free] [http://www.ncbi.nlm.nih.gov/pubmed/18596266]
This is the first report describing the molecular characterization of CTCs in lung cancer: EGFR mutations consistent with those identified in the primary tumor can be detected in CTCs. Serial analysis of (...)
Home > G. Tumoral pathology > Molecular pathology of tumors > Liquid biopsy > Circulating tumor cells > CTCs and clinical issues
CTCs and clinical issues
-
CTCs and mutation detection
18 March 2015 -
CTCs and minimal residual disease
15 March 2015Sequential peripheral blood drawings in particular for real-time monitoring of minimal residual disease in cancer patients undergoing systemic therapies are clearly more acceptable than repeated bone marrow aspirations.
Indeed, many research groups are currently assessing the clinical value of CTC analyses, which so far has been proven to provide significant prognostic information in metastatic breast cancer (Zhang et al, 2012; Bidard et al, 2014), and other solid tumors such as of the (...)
